Results 141 to 150 of about 626,622 (390)

Perioperative antithrombotic management in joint replacement surgeries [PDF]

open access: yes, 2013
Objectives To determine optimal perioperative antithrombotic management for patients with cardiac diseases undergoing joint replacement surgeries. Data sources MEDLINE and PubMed database search up to January 2013.
Chan, PK   +5 more
core   +1 more source

Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry‐based analysis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Lung ultrasound (LUS) and mortality in cardiogenic shock (CS) patients. Abstract Aims Lung ultrasound (LUS) is a widely used technique to assess de‐aeration in critically ill patients with respiratory failure. There is paucity of data on LUS in cardiogenic shock (CS).
Guido Tavazzi   +19 more
wiley   +1 more source

Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles [PDF]

open access: yes, 2016
Correspondenc
Adesanya, M. Adeola   +5 more
core   +1 more source

Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
The diagnosis of atrial cardiomyopathy (AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. The diagnostic cut‐points presented are for standard electrocardiogram and echocardiogram studies (see Figure 1 for further detail).
Jerremy Weerts   +26 more
wiley   +1 more source

Evaluation of an Unfractioned Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients [PDF]

open access: yes, 2017
Background: Despite large interpatient variability in dose response, heparin is utilized for treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in obese patients are conflicting. Objective: The objective was to evaluate
Breedlove, Emily Y.   +3 more
core   +2 more sources

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function – the Tromsø study

open access: yesHaematologica, 2012
Background Previous studies have shown an association between impaired kidney function, assessed by cystatin C-based estimated glomerular filtration rate, and venous thromboembolism.
Ellen E. Brodin   +4 more
doaj   +1 more source

Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Immune checkpoint inhibitors (ICIs) are effective against various cancers, but as more patients receive these therapies, more immune‐related adverse events (irAEs) emerge. Recent studies have suggested that ICIs are associated with an increase in pulmonary artery diameter and the ratio between pulmonary artery diameter and aortic diameter ...
Yao Xu   +11 more
wiley   +1 more source

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period [PDF]

open access: yes, 2010
Some women are at risk of forming blood clots in a deep vein during pregnancy, after a caesarean birth, or during the first few weeks after childbirth. If part of the clot breaks off and lodges in a blood vessel in the lungs, it can be life-threatening ...
Abou-Nassar   +92 more
core   +1 more source

Home - About - Disclaimer - Privacy